KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Operating Expenses (2016 - 2025)

Historic Operating Expenses for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $158.5 million.

  • NovoCure's Operating Expenses rose 440.08% to $158.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $660.8 million, marking a year-over-year increase of 1006.32%. This contributed to the annual value of $638.5 million for FY2024, which is 400.81% up from last year.
  • According to the latest figures from Q3 2025, NovoCure's Operating Expenses is $158.5 million, which was up 440.08% from $156.9 million recorded in Q2 2025.
  • In the past 5 years, NovoCure's Operating Expenses ranged from a high of $191.1 million in Q4 2024 and a low of $108.4 million during Q1 2021
  • Its 5-year average for Operating Expenses is $142.1 million, with a median of $149.3 million in 2024.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 3990.07% in 2021, then crashed by 424.23% in 2024.
  • NovoCure's Operating Expenses (Quarter) stood at $126.9 million in 2021, then rose by 12.29% to $142.5 million in 2022, then increased by 7.31% to $152.9 million in 2023, then increased by 24.95% to $191.1 million in 2024, then fell by 17.06% to $158.5 million in 2025.
  • Its Operating Expenses was $158.5 million in Q3 2025, compared to $156.9 million in Q2 2025 and $154.3 million in Q1 2025.